Mirum Pharmaceuticals, Inc.
MIRM
Rang în acțiuni
#3345
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Preț acțiune
$80.17
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$5.21B
Schimbare (1 zi)
-2.69%
Schimbare (1 an)
9.03%
Țară
US
Tranzacționează Mirum Pharmaceuticals, Inc. (MIRM)
Categorie
Healthcare
EPS pentru Mirum Pharmaceuticals, Inc. (MIRM)
EPS la data de June 2026 TTM: $-14.56
Conform celor mai recente rapoarte financiare și prețului acțiunilor Mirum Pharmaceuticals, Inc., EPS-ul actual al companiei (TTM) este $-14.56. La sfârșitul anului 2023, compania avea un EPS de $-4.00 o scădere comparativ cu EPS-ului din 2022, care a fost de $-4.01.
Istoricul EPS pentru Mirum Pharmaceuticals, Inc. din 2018 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-14.56 | 687.03% |
| 2024 | $-1.85 | -53.75% |
| 2023 | $-4.00 | -0.25% |
| 2022 | $-4.01 | 44.77% |
| 2021 | $-2.77 | -32.27% |
| 2020 | $-4.09 | 78.60% |
| 2019 | $-2.29 | 205.33% |
| 2018 | $-0.75 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -218.96% |
US
|
|
| $-7.98 | -45.19% |
US
|
|
| $-5.29 | -63.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -290.52% |
NL
|
